Karakurt Eryılmaz, MelekKaraağaç, Mustafa2021-11-012021-11-0120191078-15521477-092Xhttps://doi.org/10.1177/1078155218818250https://hdl.handle.net/11491/6781Abiraterone is an oral inhibitor of cytochrome P450 (17alpha)-hydroxylase/17,20 lyase (CYP17) complex critical to androgen production. Abiraterone in combination with prednisone is currently FDA approved for use in men with metastatic castration-resistant prostate cancer, both in the pre- and post-chemotherapy settings. This article discusses the treatment with abiraterone in a patient with metastatic castration-resistant prostate cancer on hemodialysis.eninfo:eu-repo/semantics/closedAccessAbirateronemetastatic castration-resistant prostate cancerhemodialysisArticle2582031203410.1177/1078155218818250N/AWOS:0004948554000302-s2.0-8507462512631694496Q3